Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Tambo Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity is limited to 1 distinct examiner and 1 distinct art unit, indicating a focused approach to securing its biological intellectual property. This narrow scope suggests that the company is prioritizing a specific biotechnological innovation within its current active filings at the patent office rather than pursuing a broad array of pharmaceutical applications.
BENJAMIN MICHAEL BRANDSEN is the busiest examiner for the company, managing 1 pending office action. This examiner is responsible for the total workload currently active in the portfolio. The concentration in 1 art unit suggests that the technology is being examined within a specific pharmaceutical classification, which may streamline the response process by allowing the legal team to focus on the technical standards of a single examination group.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRANDSEN, BENJAMIN MICHAEL | 1 | 60.2% | +18.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17624625 | TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY | BRANDSEN, BENJAMIN MICHAEL | 127d overdue |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17624625 | TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY | BRANDSEN, BENJAMIN MICHAEL | 1693 | §103Other | Final Rejection | 127d overdue | Pending | Jan 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial